On August 5, 2026, the FDA granted approval to Takeda for its new narcolepsy drug, oveporexton.
Live Poll
Should the government prioritize fast-tracking new brain-disorder medications despite potential long-term safety risks?
October 12, 2026
Oura Postponed IPO Amidst Pending LawsuitThe wearable technology firm deferred its Nasdaq debut while facing litigation over the accuracy of its sleep monitoring devices.
October 11, 2026
Researchers Identified Sleep Deprivation MarkersA new salivary test model identified sleep-deprived individuals with 94 percent accuracy in a recent study.
October 10, 2026
Mineralys Reported Positive Trial Results for LorundrostatNew clinical trial data show the drug effectively reduced blood pressure in patients with hypertension and sleep apnea.
October 8, 2026
Philadelphia Topped 2025 Bedbug Infestation RankingsThe city recorded the highest number of service visits for bedbug remediation across the country in 2025.
October 8, 2026
Ornate Home Added Helix Mattress Lineup to CatalogThe retailer has introduced 22 Helix Sleep models to its online store for customers across the United States.
October 7, 2026
House Passed Sunshine Protection Act in JulyLegislation to make daylight saving time permanent remains stalled as experts cite health concerns.
October 6, 2026
FDA Approved First Medication for NarcolepsyThe newly authorized treatment targets the underlying condition instead of only managing its common symptoms.
October 5, 2026
Inspire Medical Systems Will Report Earnings November 2The medical technology company will release its third quarter 2026 financial results on November 2, 2026.
October 5, 2026
Tasimelteon Trial Results Have Been ReleasedA Vanda Pharmaceuticals study shows tasimelteon helped adults with delayed sleep-wake phase disorder fall asleep earlier.
October 1, 2026
AMA Approved New CPT Codes for Nerve StimulationThe American Medical Association finalized new codes to standardize billing for hypoglossal nerve stimulation therapy.
